Shares of Aclaris Therapeutics (NASDAQ:ACRS) have been assigned a consensus recommendation of “Hold” from the eight ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $46.00.
Several research firms recently issued reports on ACRS. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a report on Friday. Leerink Swann dropped their target price on shares of Aclaris Therapeutics from $54.00 to $52.00 and set an “outperform” rating for the company in a report on Wednesday, March 28th. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 19th. Guggenheim assumed coverage on shares of Aclaris Therapeutics in a report on Thursday, February 8th. They issued a “buy” rating and a $53.00 target price for the company. Finally, BidaskClub cut shares of Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd.
A number of institutional investors have recently modified their holdings of the business. MetLife Investment Advisors LLC purchased a new position in Aclaris Therapeutics in the fourth quarter valued at about $244,000. Redmile Group LLC increased its holdings in Aclaris Therapeutics by 6.0% in the fourth quarter. Redmile Group LLC now owns 107,020 shares of the biotechnology company’s stock valued at $2,639,000 after buying an additional 6,060 shares in the last quarter. Millennium Management LLC purchased a new position in Aclaris Therapeutics in the fourth quarter valued at about $291,000. Teachers Advisors LLC increased its holdings in Aclaris Therapeutics by 8.4% in the fourth quarter. Teachers Advisors LLC now owns 42,099 shares of the biotechnology company’s stock valued at $1,038,000 after buying an additional 3,273 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in Aclaris Therapeutics by 29.4% in the fourth quarter. Deutsche Bank AG now owns 179,622 shares of the biotechnology company’s stock valued at $4,426,000 after buying an additional 40,784 shares in the last quarter. 92.19% of the stock is owned by institutional investors.
NASDAQ ACRS opened at $16.46 on Wednesday. The stock has a market cap of $514.82, a P/E ratio of -6.58 and a beta of 1.63. Aclaris Therapeutics has a 52-week low of $16.01 and a 52-week high of $33.10.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.10. The firm had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $0.80 million. analysts predict that Aclaris Therapeutics will post -4.27 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Aclaris Therapeutics (ACRS) Receives $46.00 Average PT from Analysts” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/aclaris-therapeutics-acrs-receives-46-00-average-pt-from-analysts.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.